600080.SH
ST金花
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 4.69
−2.09%Year over year
Reported trailing growth
- Revenue
- -2.3%
- EBITDA
- —
- EBIT
- -1.6%
- EPS
- -64.1%
- Free cash flow
- +92.3%
- Operating cash flow
- +250.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -2.1%
- EBITDA
- -8.8%
- EBIT
- +1.6%
- Net income
- -22.5%
- EPS
- -21.1%
- Free cash flow
- +52.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026